Dr Lal Pathlabs
- Market Cap
- ₹33,670 Cr
- P/E
- 57.48
Key Fundamentals
SmallcapHealthcare ServicesHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 28.00%
- Debt to Equity
- 0.08
- EPS (TTM)
- ₹34.90
- Book Value
- ₹163.54
- Market Cap
- ₹33,670 Cr
- P/E (TTM)
- 57.48
- P/B
- 12.27
- ROE
- 22.30%
- Dividend Yield
- 0.51%
- EBITDA
- ₹884 Cr
- 52W High
- ₹2,079.00
- 52W Low
- ₹1,272.60
- Day Range
- ₹1,940.00 – ₹2,028.20
- Volume
- 2,64,951
Peer Comparison
Healthcare › Healthcare Services › Healthcare Service Provider
| 2,006.00 | 57.48 | 33,670 | 12.27 | 0.51% | 22.30% | 28.00% | 3,034 | 587 | |
| 1,572.30 | 79.45 | 16,194 | 15.32 | 0.13% | 18.90% | 20.50% | 911 | 203 | |
| 566.00 | 52.31 | 11,738 | 7.15 | 0.18% | 13.60% | 17.80% | 1,778 | 225 | |
| 528.45 | 58.33 | 8,411 | 15.21 | 2.78% | 28.40% | 35.40% | 930 | 143 | |
| 655.80 | 51.39 | 6,595 | 5.55 | 0.00% | 8.83% | 15.30% | 1,110 | 128 | |
| 519.05 | 16.67 | 1,684 | 1.60 | 0.39% | 10.90% | 12.70% | 783 | 100 | |
| 311.50 | 38.79 | 1,622 | 5.88 | 0.14% | 14.20% | 17.30% | 346 | 41 | |
| Median 7 companies | 566.00 | 52.31 | 8,411 | 7.15 | 0.18% | 14.20% | 17.80% | 930 | 143 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 66
- Strong
- Returns, margins, earnings quality 22% weight
- Valuation
- 51
- Average
- Cheap vs sector & own history 24% weight
- Growth
- 48
- Average
- Sales & profit trajectory 9% weight
- Financial Health
- 81
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 46
- Average
- Trend strength, vol-adjusted 12% weight
- Ownership
- 44
- Weak
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 36.4%
Weaknesses
2- Stock is trading at 12.3 times its book value
- The company has delivered a poor sales growth of 11.8% over past five years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 2 | 6 | 11 |
| Oscillators | Bearish | 2 | 6 | 1 |
| Moving Averages | Strong Bullish | 0 | 0 | 10 |
Oscillators
Bearish
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 57.81
- Neutral
- MACD (12,26,9)
- 20.37
- Bearish
- SMA (50)
- 1,936.16
- Bullish
- SMA (200)
- 1,680.96
- Bullish
As of
Analyst Rating
17 of 25 analysts rate Buy, 4 Hold, 4 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 10Y | +13.32% |
|---|---|
| 5Y | +11.81% |
| 3Y | +11.06% |
| 1Y | +12.27% |
| TTM | +16.69% |
Net profit
| 10Y | +14.39% |
|---|---|
| 5Y | +11.50% |
| 3Y | +28.39% |
| 1Y | +3.66% |
| TTM | +8.70% |
Operating cash flow
| 10Y | +14.87% |
|---|---|
| 5Y | +9.83% |
| 3Y | +11.73% |
| 1Y | +11.78% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +1.79 pp |
|---|---|
| 5Y | +0.76 pp |
| 3Y | +4.05 pp |
| 1Y | −0.02 pp |
| TTM | +1.05 pp |
Revenue by year
| Mar 2017 | ₹912 Cr |
|---|---|
| Mar 2018 | ₹1,057 Cr |
| Mar 2019 | ₹1,203 Cr |
| Mar 2020 | ₹1,330 Cr |
| Mar 2021 | ₹1,581 Cr |
| Mar 2022 | ₹2,087 Cr |
| Mar 2023 | ₹2,017 Cr |
| Mar 2024 | ₹2,227 Cr |
| Mar 2025 | ₹2,461 Cr |
| Mar 2026 | ₹2,763 Cr |
Net profit by year
| Mar 2017 | ₹156 Cr |
|---|---|
| Mar 2018 | ₹172 Cr |
| Mar 2019 | ₹200 Cr |
| Mar 2020 | ₹228 Cr |
| Mar 2021 | ₹296 Cr |
| Mar 2022 | ₹350 Cr |
| Mar 2023 | ₹241 Cr |
| Mar 2024 | ₹362 Cr |
| Mar 2025 | ₹492 Cr |
| Mar 2026 | ₹510 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
As of 2026-11-16, Dr Lal PathLabs Ltd trades at ₹2,000.70 with a market cap of ₹33,581.51 crore and a PE (TTM) of 57.33. The company is nearly debt-free with a debt-to-equity ratio of 0.08 and maintains a consistent ROE of around 22% over the past decade, though revenue growth has been modest at 11% CAGR over three years and the stock trades at 12.24 times book value.
- The company is virtually debt-free with a debt-to-equity ratio of just 0.08, providing significant financial flexibility and resilience through economic cycles.
- Return on equity has remained consistently strong at 22% over 3-year, 5-year, and 10-year periods, indicating durable capital efficiency and a wide economic moat in diagnostics.
- Return on capital employed stands at 25.67%, reflecting disciplined capital allocation and strong underlying profitability of the asset-light diagnostics model.
- TTM revenue growth has accelerated to 17%, meaningfully above the 3-year compounded sales growth of 11% and the 5-year rate of 12%, suggesting improving business momentum.
- Compounded profit growth over 3 years stands at 30%, significantly outpacing the 3-year sales CAGR of 11%, pointing to operating leverage and margin expansion.
- The stock has delivered a 1-year return of 28%, rising from a 52-week low of ₹1,272.60 to ₹2,000.70, reflecting renewed investor confidence in the growth trajectory.
- The company maintains a healthy dividend payout ratio of 36.4% with a current yield of 0.5%, demonstrating shareholder-friendly capital return alongside reinvestment for growth.
- 10-year compounded profit growth of 15% and sales growth of 13% demonstrate the company's ability to sustain long-term earnings expansion across market cycles.
- Price-to-book ratio of 12.24 times is elevated, meaning investors are paying a significant premium over the company's net asset value for expected future earnings.
- Five-year compounded sales growth of only 12% is modest for a stock commanding a 57x earnings multiple, raising questions about whether the valuation is justified by the growth rate.
- The 5-year stock CAGR of just 2% indicates prolonged periods of poor price returns despite underlying business growth, suggesting the market periodically reprices the premium downward.
- TTM profit growth of 13% has decelerated sharply from the 3-year compounded rate of 30%, which may signal that the margin expansion phase is normalising.
- The dividend yield of 0.5% offers minimal income return relative to risk-free alternatives, making the stock largely dependent on capital appreciation for total returns.
- At ₹2,000.70, the stock is trading near its 52-week high of ₹2,079, leaving only about 3.9% headroom before the recent ceiling and raising the risk of near-term mean reversion.
- Five-year ROE averaged 21%, slightly below the 10-year average of 22%, suggesting return on equity has plateaued rather than expanded despite scale gains.
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Dr Lal PathLabs delivered its strongest quarterly growth in five years with 19.6% revenue growth and 27.5% profit expansion in Q2FY27, supported by healthy 9% patient volume gains and margin improvement to 32.1%. Management's high-teens revenue growth guidance for FY27 signals continued momentum. No material headwinds emerged this cycle. The trend is clearly improving, and sustained volume growth alongside CGHS price tailwinds positions the company well heading into H2FY27.
- Strong Q2 revenue up 19.6% Nov 10
Revenue grew 19.6% YoY to ₹874 crore in Q2FY27, the highest quarterly growth in five years. Patient volumes rose 9% YoY, driving operational leverage.
- Net profit jumps 27.5% YoY Nov 10
Net profit rose 27.5% YoY to ₹194 crore with EBITDA margin expanding to 32.1%, reflecting improved realisations and cost efficiency.
- High-teens revenue growth guided Nov 10
Management guided for high-teens revenue growth for FY27, with CGHS price hikes expected to contribute 2-3% additionally.
- Shareholder vote for new director Nov 12
Postal ballot issued for appointment of Vasuta Agarwal as Independent Director, with e-voting open from November 14 to December 13, 2026.
- Investor conferences in Mumbai Nov 11
Dr. Lal PathLabs will participate in investor conferences in Mumbai on November 16 and 17, 2026.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 601 | 539 | 545 | 602 | 660 | 597 | 603 | 670 | 731 | 660 | 703 | 798 | 874 |
| Expenses | 424 | 398 | 401 | 432 | 458 | 443 | 434 | 478 | 506 | 480 | 516 | 550 | 594 |
| Operating Profit | 178 | 141 | 145 | 170 | 202 | 154 | 169 | 192 | 224 | 179 | 187 | 248 | 280 |
| OPM % | 30% | 26% | 27% | 28% | 31% | 26% | 28% | 29% | 31% | 27% | 27% | 31% | 32% |
| Other Income | 18 | 18 | 18 | 21 | 22 | 25 | 26 | 28 | 25 | 24.4 | 24 | 32 | 34.3 |
| Interest | 8 | 7 | 7 | 6 | 6 | 5 | 5 | 5 | 5 | 7 | 6 | 6 | 7 |
| Depreciation | 36 | 36 | 37 | 35 | 35 | 36 | 36 | 35 | 40 | 42 | 45 | 44 | 46.9 |
| Exceptional Items | — | — | — | — | — | — | — | — | — | −30.1 | — | — | — |
| PBT | 152 | 116 | 120 | 150 | 183 | 138 | 153 | 181 | 204 | 124 | 160 | 229 | 261 |
| Tax % | 27% | 29% | 28% | 28% | 29% | 29% | −1% | 26% | 25% | 26% | 17% | 25% | 26% |
| Net Profit | 111 | 82 | 86 | 108 | 131 | 98 | 156 | 134 | 152 | 91 | 132 | 170 | 194 |
| EPS (₹) | 6.55 | 4.87 | 5.06 | 6.37 | 7.73 | 5.78 | 9.26 | 7.90 | 8.99 | 5.40 | 7.84 | 10.11 | 11.55 |
| YoY Sales growth | 13 | 10 | 11 | 11 | 10 | 11 | 10 | 11 | 11 | 11 | 17 | 19 | 20 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 660 | 791 | 912 | 1,057 | 1,203 | 1,330 | 1,581 | 2,087 | 2,017 | 2,227 | 2,461 | 2,763 | 3,034 |
| Expenses | 504 | 582 | 675 | 793 | 910 | 987 | 1,145 | 1,526 | 1,527 | 1,617 | 1,764 | 1,979 | 2,140 |
| Operating Profit | 156 | 210 | 238 | 264 | 294 | 344 | 436 | 561 | 490 | 609 | 698 | 783 | 894 |
| OPM % | 24% | 26% | 26% | 25% | 24% | 26% | 28% | 27% | 24% | 27% | 28% | 28% | 29% |
| Other Income | 12 | 20 | 27 | 31 | 46 | 55 | 51 | 52 | 42 | 69 | 91 | 70 | 84 |
| Interest | 0 | 0 | 1 | 1 | 1 | 15 | 16 | 30 | 38 | 29 | 22 | 23 | 27 |
| Depreciation | 28 | 28 | 28 | 33 | 38 | 73 | 77 | 108 | 150 | 144 | 142 | 162 | 178 |
| PBT | 140 | 201 | 237 | 261 | 301 | 310 | 394 | 475 | 344 | 505 | 625 | 669 | 774 |
| Tax % | 31% | 34% | 34% | 34% | 33% | 27% | 25% | 26% | 30% | 28% | 21% | 24% | — |
| Net Profit | 96 | 133 | 156 | 172 | 200 | 228 | 296 | 350 | 241 | 362 | 492 | 510 | 588 |
| EPS (₹) | 8.75 | 7.99 | 9.31 | 10.24 | 11.95 | 13.55 | 17.49 | 20.69 | 14.33 | 21.42 | 29.14 | 30.13 | 34.90 |
| Div. Payout % | 9% | 15% | 16% | 22% | 25% | 44% | 57% | 29% | 42% | 0% | 41% | 68% | — |
| Sales growth | 18 | 20 | 15 | 16 | 14 | 11 | 19 | 32 | −3 | 10 | 11 | 12 | 17 |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 55 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 84 | 168 | 168 |
| Reserves | 260 | 425 | 512 | 705 | 862 | 949 | 1,162 | 1,418 | 1,583 | 1,766 | 2,089 | 2,341 | 2,577 |
| Borrowings | 27 | 0 | 0 | 0 | 0 | 0 | 150 | 533 | 420 | 247 | 157 | 199 | 233 |
| Other Liabilities | 134 | 118 | 95 | 128 | 145 | 341 | 265 | 309 | 297 | 357 | 383 | 433 | 480 |
| Total Liabilities | 475 | 625 | 690 | 916 | 1,091 | 1,374 | 1,661 | 2,343 | 2,383 | 2,454 | 2,713 | 3,140 | 3,458 |
| Fixed Assets | 150 | 166 | 152 | 208 | 209 | 413 | 447 | 1,369 | 1,305 | 1,228 | 1,168 | 1,256 | 1,310 |
| CWIP | 1 | 4 | 18 | 10 | 3 | 11 | 10 | 15 | 5 | 6 | 3 | 7 | 5 |
| Investments | 38 | 64 | 106 | 145 | 185 | 164 | 59 | 65 | 150 | 114 | 327 | 423 | 530 |
| Other Assets | 286 | 391 | 414 | 554 | 694 | 786 | 1,144 | 893 | 923 | 1,107 | 1,215 | 1,454 | 1,612 |
| Total Assets | 475 | 625 | 690 | 916 | 1,091 | 1,374 | 1,661 | 2,343 | 2,383 | 2,454 | 2,713 | 3,140 | 3,458 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 122 | 159 | 171 | 197 | 219 | 284 | 398 | 447 | 456 | 535 | 569 | 636 |
| Investing | −113 | −163 | −137 | −172 | −100 | −26 | −212 | −449 | −287 | −24 | −303 | −422 |
| Financing | −1 | 0 | −32 | 13 | −55 | −190 | −139 | 136 | −283 | −414 | −334 | −264 |
| Net Cash Flow | 8 | −5 | 2 | 37 | 64 | 67 | 48 | 134 | −114 | 97 | −68 | −50 |
| Free Cash Flow | 87 | 115 | 120 | 125 | 177 | 205 | 339 | −28 | 412 | 479 | 516 | 463 |
| CFO/EBITDA | 112 | 108 | 102 | 110 | 110 | 110 | 115 | 103 | 115 | 110 | 105 | 104 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 17 | 17 | 17 | 14 | 16 | 14 | 15 | 15 | 13 | 13 | 13 | 15 |
| Inventory Days | 37 | 31 | 33 | 44 | 40 | 70 | 39 | 38 | 28 | 30 | 27 | 30 |
| Days Payable | 90 | 89 | 97 | 106 | 111 | 144 | 132 | 107 | 127 | 151 | 127 | 123 |
| Cash Conversion Cycle | −35 | −42 | −47 | −47 | −55 | −60 | −78 | −54 | −87 | −108 | −86 | −79 |
| Working Capital Days | −9 | 27 | 19 | 17 | 0 | −19 | −26 | −54 | −56 | −46 | −30 | −29 |
| ROCE % | 48% | 47% | 43% | 38% | 35% | 32% | 33% | 29% | 18% | 25% | 29% | 28% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Dr Lal Pathlabs insights
66 extracted metrics across FY14–FY27.
Documents
- Q2 FY27 concall · Nov 2026Transcript PPT Recording
- Q1 FY27 concall · Jul 2026Transcript PPT Recording
- Q4 FY26 concall · May 2026Transcript PPT Recording
- Q3 FY26 concall · Feb 2026Transcript PPT Recording
- 4 Nov 2026
- 1 Apr 2026
- 22 Apr 2025
- 17 Mar 2025
- 14 Feb 2024
- 8 May 2023
- General announcements 11 Nov 2026
Frequently Asked Questions about Dr Lal Pathlabs
What does Dr Lal Pathlabs Ltd do?
Where is Dr Lal Pathlabs Ltd (LALPATHLAB) listed?
Which sector does Dr Lal Pathlabs Ltd belong to?
What is the market capitalisation of Dr Lal Pathlabs Ltd?
What is the PE ratio of Dr Lal Pathlabs Ltd?
What is the 52-week high and low of Dr Lal Pathlabs Ltd?
Does Dr Lal Pathlabs Ltd pay dividends?
What is the Return on Equity (ROE) of Dr Lal Pathlabs Ltd?
Company Information
Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/LALPATHLAB.md for Dr Lal Pathlabs Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.